Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2000
Business Overview: The Company operates in two primary segments: Animal Health Products and Research & Development (R&D). Its principal customers are in the United States dairy and beef industries, accounting for approximately 84% of product sales. Key products include FIRST DEFENSE(R) and the KAMAR(R) HEATMOUNT(TM) DETECTOR.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Total Revenues | $1,447,020 | $1,403,600 |
| Net Profit | $227,014 | $253,899 |
| Net Profit Per Share (Diluted) | $0.08 | $0.10 |
| Cash and Cash Equivalents | $2,103,020 | $1,571,163 |
| Net Cash from Operating Activities | $23,947 | $63,312 |
| Total Debt (Long-term + Current) | $448,774 | $453,349 |
| Working Capital | $2,733,877 | $2,219,386 |
Note: Gross margin on product sales was 53% for Q1 2000, down from 57% in Q1 1999.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by approximately 3% ($43,420) compared to Q1 1999. Product sales rose 5% ($66,180), driven by the introduction of WIPE OUT(TM) DAIRY WIPES, though sales of core products (FIRST DEFENSE and KAMAR HEATMOUNT) declined 6% due to order backlogs.
- Profitability: Net profit decreased by approximately 11% ($26,885) to $227,014. This decline was primarily due to a reduction in grant income (down $25,966) and a lower gross margin percentage.
- Expense Management: Research and development expenses decreased significantly by 31% ($71,417) to $161,392, reflecting a strategic shift away from human health markets toward animal health. Conversely, sales and marketing expenses increased by 20% ($45,769).
- Liquidity: Cash and cash equivalents increased by $279,332, largely due to $266,716 in proceeds from the exercise of stock options. Net cash provided by operating activities decreased to $23,947 from $63,312 in the prior year.
Outlook, Risks, and Management Commentary
- Product Pipeline: Management anticipates filling a backlog of approximately $250,000 in FIRST DEFENSE orders in the second quarter of 2000. Sales of TIP-TEST(TM): JOHNE'S remain limited due to state regulatory barriers.
- Strategic Focus: The Company continues to invest in animal health products to manage disease and reproduction in herds, as well as a product to detect infectious pathogens in water. Management believes current capital resources are sufficient for the next twelve months.
- Grant Funding: Approximately $55,000 remains available under a Phase II Small Business Innovation Research grant for the DiffGAM clinical development program.
- Risks: Forward-looking statements are subject to risks regarding product development delays, regulatory approvals, and market competition. The Company has no provision for income taxes due to net operating loss carryforwards.
Investor Verification Checklist
- Order Backlog: Verify the realization of the $250,000 FIRST DEFENSE order backlog in Q2 2000.
- Regulatory Hurdles: Monitor progress on overcoming state regulatory barriers for TIP-TEST(TM): JOHNE'S sales.
- Product Mix Margins: Assess the long-term impact of lower-margin products (WIPE OUT) on overall gross margins.
- Debt Obligations: Review the mortgage loan terms (8.62% fixed rate) and the balloon payment structure due in 2003.
- Stock Dilution: Note the issuance of 181,100 shares via option exercises in Q1 2000 and its impact on future earnings per share.